In this study, we tested the feasibility of non-invasively measuring phosphoarginine (PArg) after gene delivery of arginine kinase (AK) using an adeno-associated virus (AAV) to murine hindlimbs. This was achieved by evaluating the time course, regional distribution and metabolic flux of PArg using 31 phosphorus magnetic resonance spectroscopy ( 31 P-MRS). AK gene was injected into the gastrocnemius of the left hindlimb of C57Bl10 mice (age 5 weeks, male) using self-complementary AAV, type 2/8 with desmin promoter. Non-localized 31 P-MRS data were acquired over 9 months after injection using 11.1-T and 17.6-T Bruker Avance spectrometers. In addition, 31 P two-dimensional chemical shift imaging and saturation transfer experiments were performed to examine the spatial distribution and metabolic flux of PArg, respectively. PArg was evident in each injected mouse hindlimb after gene delivery, increased until 28 weeks, and remained elevated for at least 9 months (Po0.05). Furthermore, PArg was primarily localized to the injected posterior hindimb region and the metabolite was in exchange with ATP. Overall, the results show the viability of AAV gene transfer of AK gene to skeletal muscle, and provide support of PArg as a reporter that can be used to non-invasively monitor the transduction of genes for therapeutic interventions.
INTRODUCTION
Evaluating gene therapies targeted at treatment of skeletal muscle diseases frequently relies on histological analysis from tissue extracts or muscle biopsies to determine the extent to which regions have been transduced. [1] [2] [3] However, a number of non-invasive approaches has shown promise in detecting reporter genes with the potential to obtain longitudinal measures within the same animal or human over time, including optical imaging, 4, 5 positron emitting radioisotopes 6 and magnetic resonance imaging and spectroscopy (MRS). 7 Magnetic resonance imaging-based approaches offer high spatial resolution, and include administration of paramagnetic compounds to alter T 1 contrast (for example, gadolinium), superparamagnetic and ferromagnetic agents that enhance T 2 and T 2 * (for example, iron oxide particles) 8 and chemical exchange saturation transfer-based reporter genes. 7, 9 In addition, MRS has been used to detect metabolites of gene products. For example, 31 phosphorus MRS ( 31 P-MRS) was used to measure the creatine kinase (CK) activity after CK transgenic overexpression 10 and virally mediated gene transfer to the liver. 11, 12 Although magnetic resonance (MR) gene reporter applications to skeletal muscle have generally been limited in the literature, one promising method involves the viral-mediated gene transfer of arginine kinase (AK) into mammalian muscle to result in the production of phosphoarginine (PArg), which can be detected using 31 P-MRS. 13 AK is typically found in invertebrates and catalyzes the rephosphorylation of ADP to ATP at the cost of PArg (Equation 1), and CK is the functionally similar enzyme of vertebrates with phosphocreatine (PCr) as the phosphate donor (Equation 2). The gene delivery of AK is ideally suited to act as a reporter gene as it provides a unique MR signal against a mammalian background, its coding sequence is small enough to be expressed with therapeutic genes, and it does not appear to interfere with normal tissue function. 13 PArg
In a previous study, delivery of AK gene to skeletal muscle of mice hindlimbs was performed using an adenovirus. 13 However, in order to expand on the potential application of AK gene delivery, in this study we tested the feasibility of using a selfcomplementary (sc) adeno-associated virus (AAV) to deliver the AK gene with production of PArg monitored over time with 31 P-MRS. Using an AAV for delivery is expected to improve biosafety, reduce immune response and toxicity, and increase long-term expression resulting in improved efficacy for in vivo use compared with an adenovirus.
14-17 Furthermore, we determined the time course of PArg accumulation, regional distribution using 31 P 2D chemical shift imaging (CSI) and enzyme activity of AK and CK using 31 P-MRS saturation transfer experiments.
RESULTS
In this study, AK gene was delivered to the gastrocnemius muscle of mice using scAAV type 2/8 with desmin promoter, and PArg, PCr, inorganic phosphate (P i ), ATP and intracellular pH (pH i ) were monitored using 31 P-MRS over 9 months after injection. In the posterior hindlimbs in which the AK gene was delivered, PArg was evident in each of the mice (n ¼ 5) as measured by 31 P-MRS ( Figure 1 ). Consistent with the 31 P-MRS data, the existence of AK in the injected gastrocnemius muscle was confirmed using immunoblotting. On the other hand, PArg was not evident in the contralateral limb, nor was AK detected in the contralateral limb using immunoblotting (Figure 1 ).
In the hindlimb in which the AK gene was delivered, PArg signal was evident after 1 week, increased (Po0.05) until 28 weeks after gene delivery and then remained elevated for at least 37 weeks (Figure 2 ). The presence of PArg was evident as a distinct peak in the 31 P-MRS spectra in each injected mouse hindlimb 8 weeks after gene delivery (Figure 1 ). During the initial 4 weeks following gene delivery, the PArg peak was typically evident as a 'shoulder' on the PCr peak or a separate small peak that stemmed from the PCr peak. These peaks were analyzed in the time domain using prior knowledge of the relative peak positions (PCr and PArg separated by 0.44 p.p.m.); using this method, we were able to discriminate the PCr and PArg peaks. Fitting both PCr and PArg reduced the residuals and improved the fitting of the spectra in the limbs with AK gene delivered compared with only fitting the PCr peak, providing evidence that PArg was in the muscle at least as early as 1 week.
The transgene delivery of AK and the subsequent increase of PArg did not appear to affect PCr or P i concentration nor pH i of the muscle over time, with these measures remaining similar throughout the 9 months (Table 1 ). Compared to the limb with AK gene delivered, the contralateral limb was observed to have a greater (P ¼ 0.04) concentration of PCr (34.2 ± 4.8 vs 26.9±1.5 mM), with a similar concentration of P i (6.2±2.5 vs 6.0 ± 1.3 mM) and pH i (7.10 ± 0.06 vs 7.13 ± 0.08). The contralateral limb of the mice with AK gene delivery was similar (P40.05) to the control wild-type hindlimbs for PCr (33.1 ± 3.3 mM), P i (4.30±3.1 mM) and pH i (7.16±0.16). Furthermore, using localized 2D 31 P CSI, PArg was shown to be localized to the injected posterior hindlimb region, and was not evident in deeper regions of the lower hindlimb ( Figure 3 ).
Saturation transfer experiments Unidirectional rates and fluxes for PCr-ATP, PArg-ATP and P i -ATP in hindlimb muscles of mice after AK gene transfer were estimated using saturation transfer experiments. The measures of reaction fluxes were based on 31 P-MRS measures of PCr and PArg at equilibrium and under g-ATP saturation conditions, as well as with estimates of apparent T 1 (T 1 0 ) of PCr, PArg and P i . T 1 0 was calculated to be similar (P40.05) in PCr (1.07 ± 0.27 s), PArg (1.02 ± 0.43 s) and P i (1.06 ± 0.25 s) at 17.6 T.
The saturation transfer experiments revealed that PArg was in chemical exchange with ATP, with the rate constant being several-fold lower in the AK than the CK reaction ( Table 2) . Together with a lower concentration of PArg relative to PCr, the overall flux through the AK reaction was less (Po0.05) than through the simultaneous CK reaction ( Figure 4 ; Table 2 ). In addition, the fluxes for P i -ATP in hindlimb muscles were observed to be similar (P40.05) in mice after AK gene transfer 1.03±0.37 mM*s À 1 ) and in controls (1.02±0.21 mM*s À 1 ).
DISCUSSION
In this study, we tested the viability using recombinant scAAV gene transfer of AK gene to skeletal muscle of mice at 5 weeks of age. The main findings of this study were that: (1) AK gene was successfully delivered to muscle as detected by PArg in 31 P spectra and AK in tissue with immunoblotting; (2) an increase of PArg accumulation was observed non-invasively up to 28 weeks, then levels were maintained until at least 9 months; (3) PArg was primarily localized in the posterior hindlimb, proximal to the gene delivery injection site; and (4) PArg was in chemical exchange with ATP, with the flux through this reaction being less than the simultaneous CK reaction. Collectively, the results support that AAV delivery of the AK gene is effective in providing a gene reporter that can be non-invasively monitored using MR in skeletal muscle.
Function of AK AK is typically found in invertebrates, whereas CK provides a similar function in mammalian muscle; although there are invertebrates in which both AK and CK have been observed to co-exist in the same cells, such as in the starlet sea anemone Nematostella vectensis. 18 In this study, we observed both PCr and PArg simultaneously in the mouse hindlimb in the region of AK gene delivery, with lower rate constants and overall flux at rest through the AK than the CK reaction ( Table 2) . Consistent with this, Ellington 1989 observed the equilibrium constant of AK to be B13% of the CK reaction in vitro using both enzymatic analysis and 31 P-MRS saturation experiments. 19 Furthermore, during 1 h of muscle ischemia in a previous study, PCr was depleted to a greater extent (77%) than PArg (50%), consistent with a reduced equilibrium constant. 13 The similar P i -ATP flux observed between the hindlimb injected with AK gene and controls suggests that net ATP synthesis rate was similar between groups, although the factors that contribute to this measure are not easily interpreted and include contributions from both glycolytic and oxidative sources. 20 Furthermore, with PArg concentration elevated, PCr concentration reduced, and no change in total PArg and PCr in the hindlimbs with AK gene transfer compared with controls, this may be expected to have implications for energy balance under certain conditions. As a result of the higher equilibrium constant of the CK reaction, a primary function of the CK reaction is expected to be the maintenance of ATP levels at the onset of muscle of contractions and during burst activity, whereas PArg may provide an additional ATP buffer to skeletal muscle, particularly under low PCr and ATP levels. Therefore, the AK reaction would be expected to have a relatively greater role during fatiguing and acidic conditions. 13, 19 As a result, it is possible that AK gene transfer could provide a viable therapeutic approach in ischemic states, perhaps in a similar manner, but possibly to a greater extent, than that observed previously with administration of cyclocreatine. [21] [22] [23] [24] Overall, the persistent flux observed through the AK reaction in this study provides support that PArg is in exchange with ATP and this reaction is metabolically active at rest in the muscle. 31 P spectra with and without saturation of g-ATP acquired at 17.6T (a). The saturation transfer experiments revealed that PArg was in chemical exchange with g-ATP, with the rate of the reaction being less than through the simultaneous creatine kinase reaction (b).
Delivery of AK gene using AAV The combination of scAAV serotype 2/8 with desmin reporter used in this study was anticipated to result in an efficient and safe transgene delivery to skeletal muscle. AAV has emerged as a safe form of gene delivery with a minimal cellular immune response, as it does not efficiently transduce antigen-presenting cells. 17, 25, 26 Furthermore, AAV has been shown to achieve stable forms of gene expression of up to 4 years in human subjects, 27 and has been widely used in a number of clinical studies targeting various tissues, including skeletal muscle in treating dystrophies. 1, 28 In a previous study, PArg was monitored in mice with 31 P-MRS after delivery of AK gene using an adenovirus. 13 In that study, the mice were injected at the neonatal stage (1-3 days of age) with a cytomegalovirus promotor. The gene transfer at a younger age in that study may have contributed to greater PArg accumulation compared with the present study. However, the adenovirus vector used in that study may have limited applicability due to the potential of activating an innate immune response 29 and developing neutralizing antibodies that may block vector readministration. 30 On the other hand, although immune responses were not directly measured in this study, the results show the feasibility of using an AAV delivery of AK gene, which is expected to improve efficacy for in vivo use. [14] [15] [16] Although the results of this study are encouraging, there are obstacles remaining before AAV AK gene delivery could be used in combination with therapeutic interventions, particularly in humans. Challenges include optimizing delivery methods to a greater number of muscles/tissues and avoiding or minimizing an immune response, particularly when moving to larger animal models and in humans. In order to improve distribution, other methods should be investigated, such as systemic delivery methods, 31 perhaps in combination with a skeletal muscle ischemia intervention. 32 A number of AAV serotypes has been effectively used in skeletal muscle, including the AAV2/8 serotype used in this study. AAV2/8 transduces both type I and II skeletal muscle fibers efficiently with minimal inflammatory and immune responses in mice. 26 In wild-type mice, six AAV serotypes (AAV2/1, 2, 2/5, 2/7, 2/8 and 2/9) were compared, and AAV2/8 was shown to have the highest transgene expression for muscle-directed gene therapy, with no immune cell response identified. 33 In addition, AAV2/8 effectively delivered microdystrophin and demonstrated restoration of dystrophin in a beagle-based dystrophic dog model, CXMDj. 33 Therefore, there is considerable support for AAV serotype 2/8 being effective for transgene delivery to skeletal muscle.
In this study, a desmin promoter was used with the AAV delivery. Desmin is an intermediate filament located at the periphery of the Z-disks of striated muscle, and has been shown to contribute to the structural integrity and function of muscle. 34 When compared with cytomegalovirus, alpha-myosin heavy chain, myosin light chain 2 and cardiac troponin C promoters, desmin promoter with a myocyte-specific enhancer factor 2 and a MyoD enhancer element showed the greatest expression of LacZ following IV administration of rAAV2/9-mediated gene delivery in skeletal muscle of newborn mice. 35 Also, human desmin promoter matched the activity of human cytomegalovirus promoter with lentiviral vector delivery to hindlimb skeletal muscle of neonatal mice, with the desmin promoter providing several-fold greater expression than the muscle-specific human muscle CK promoter. 36 Furthermore, desmin promoter was used as a muscle-specific promoter in the effective delivery and restoration of dystrophin in 1-5% of the myofibers of the injected hindlimb of mdx mice. 37 Time course of accumulation of PArg after rAAV delivery In this study, we observed that PArg was evident within 1 week, peaked at 28 weeks, and was maintained until at least 9 months.
Although it is not possible to determine whether the rate of increase in PArg was limited by AK activity or arginine availability with the measures that we obtained in this study, the presence of PArg confirms AK gene expression. Furthermore, AK expression was observed with immunoblotting. The time course of protein expression has been shown to be highly dependent on a number of factors, including AAV serotype, tissue and species. 38 In this study, scAAV vectors were utilized, which packages a doublestranded genome and eliminates the need for complementary strand synthesis. 39, 40 Although scAAV has the drawback that the size of the DNA packaging capacity of the expression cassette is half of the traditional single-stranded AAV (ssAAV), scAAV offers the advantage of faster onset and greater expression than ssAAV vectors in muscle. 40 Consistent with a rapid onset of AK expression, we observed evidence of PArg accumulation within 1 week using 31 P-MRS. In a previous study, comparing scAAV and ssAAV transgene delivery to the tibialis anterior in mice, strong expression was observed after 1 week using scAAV but minimal expression was noted in ssAAV using florescence. 41 In that study, the transgene expression using scAAV reached a plateau by 6 weeks and maintained a high level for the 6 months duration of the experiment, whereas the transgene expression of ssAAV increased slowly by 6 weeks and continued to increase until at least 6 months; at the end of 6 months, the scAAV had 15-fold greater expression than ssAAV. 41 Similarly, using scAAV has been shown to result in expression of the myocardium within 4 days in small animals 42 and 1 week of canines. 39 Overall, the combination of scAAV serotype 2/8 with desmin reporter used in this study was shown to be effective in the transgene delivery of AK gene to skeletal muscle of mice.
In summary, the results of this study support the use of 31 P-MRS to monitor PArg non-invasively in mammalian muscle, providing a robust way of evaluating the transduction of gene expression. The distinct resonance frequency of PArg provides a unique signal that can be non-invasively evaluated. In this study, we exploited high-field strength MR to further enhance chemical shift differences between PCr and PArg and two-dimensional (2D) 31 P CSI provided spatial information of gene transduction. Although magnetic resonance imaging measures of reporter genes have the potential to provide high spatial resolution, these methods are often affected by non-specific coinciding variables associated with vector delivery or disease process, such as inflammation. 8 Overall, the results of this study using 31 P-MRS show the viability of AAV gene transfer of AK gene to skeletal muscle of mice, and provide support for use as a gene reporter to non-invasively monitor the delivery of genes for therapeutic interventions.
MATERIALS AND METHODS Animals
Wild-type C57BL/10ScSn mice (male; n ¼ 10) were obtained from Jackson Laboratories (Bar Harbor, ME, USA), and thereafter maintained in-house in an Association for Assessment and Accreditation of Laboratory Animal Care-approved facility with a 12-h light:dark cycle (72 1F, 42% humidity) and free access to food and water. The experimental protocol was approved by the Institutional Animal Care and Use Committee at the University of Florida.
Injection
Direct intramuscular injection of replication-deficient AAV encoding for the AK gene into the hindlimb of mice was performed as previously described. 17, 43 Specifically, scAAV, type 2/8 with desmin promoter (5.0 Â 10 10 particles per leg) were delivered with 80 ml of phosphatebuffered saline to the left gastrocnemius of the mice. Five mice received the injection with encoding for the AK gene, and the remaining five mice served as controls.
Magnetic resonance spectroscopy
The mice were anesthetized using an oxygen (1 l min À 1 ) and isoflurane mixture (3% isoflurane) and maintained with 1% isoflurane in O 2 delivered through an anesthesia mask with a scavenger valve for the duration of the MR procedure. Body temperature was maintained through an MR compatible heating system that provided heated air into the bore of the magnet, and respiratory rate was monitored for the duration of the scans (Small Animal Instruments, Inc. (SAII), Stony Brook, NY, USA). 31 P-MRS data were acquired using 11.1-T 40 cm horizontal bore and 17.6-T 89 mm vertical bore systems with Bruker Avance spectrometers (Paravision, Version 3.02 and 4.0, Bruker Corporation, Billerica, MA, USA). Mice were positioned prone with the hindlimb being extended, and an oblong transmit/receive 31 P surface coil (6 Â 12 mm 2 ) centered on the posterior region of the lower hindlimb (11.1-T, 190.6 mHz: built in-house; 17.6-T, 303.7 mHz: Doty Scientific, Columbia, SC, USA). Also, a 1 H-tuned surface coil was placed adjacent to the hindlimb for localized shimming of the posterior hindlimb region. 31 P data were collected at weekly intervals for the initial 4 weeks after gene delivery, then at 2-to 6-week intervals up to 37 weeks using an 11.1-T (TR 2 s, 256 NSA, 2048 data points, 8 kHz spectra width) or a 17.6-T (TR 2 s, 256 NSA, 8096 data points, 10 kHz spectra width) system. 31 P-MRS data of the contralateral limb were acquired at 28 weeks after AK gene transfer. Furthermore, 31 P-MRS data from a hindlimb of the non-injected control mice were acquired at 30 weeks of age.
In addition, at 16 weeks after gene transfer, 31 P 2D CSI was acquired (8 Â 8 matrix, 10-15 mm field of view, 3 mm axial slice thickness, TR 2 s, 32 NSA, 4096 data points, spectral width 10 kHz) at 11.1-T to examine the spatial distribution of PArg in the mouse hindlimb. In addition, we performed 31 P saturation transfer experiments at 17.6-T in the injected hindlimb after 28-32 weeks of gene delivery using selective saturation of g-ATP for 2, 4, 6 and 8 s (gauss pulse shape, pulse length 12 msec, with an interpulse delay of 200 msec, power 1.2 mT). The spectra were acquired using 32 averages with a TR of 10 s (excitation pulse shape bp32, 50 msec). Spectra were also acquired with a saturation frequency that mirrored the difference in frequency of the center of PCr and PArg, and g-ATP (665±8 Hz) to account for any radiofrequency bleeding.
Magnetic resonance spectroscopy analysis To account for partial saturation, signal intensities were multiplied by correction factors derived using spectra acquired with a TR of 2 and 15 s at 11.1-T (PCr, 1.45 ± 0.33; PArg, 1.46 ± 0.36; g-ATP, 1.33 ± 0.40; P i , 1.87±0.25) and 17.6-T (PCr, 1.07±0.04; PArg, 1.08±0.04; g-ATP, 1.08±0.04; P i , 1.26±0.11). Concentrations of PCr, PArg and P i were calculated assuming an ATP concentration of 8.7 mM. 13 
31
P 2D-CSI. Analyses of the localized phosphorus spectra were performed using 3DiCSI software (Version 1.9.9). 44 Spectra were viewed in an 8 Â 8 matrix, then zero-filled (16 Â 16), phased and the corresponding free induction decays within the regions of interest (that is, posterior and medial compartment) were exported and analyzed using the jMRUI software (Version 5.0). Analyses of the spectra were performed by aligning the spectra, setting the PCr peak to 0 p.p.m., and summing the spectra within each compartment to produce a single spectrum.
Saturation transfer experiments
The rates of transfer of phosphate from PCr and PArg to g-ATP were estimated by saturation transfer using a pseudo-first-order exchange model. [45] [46] [47] The exchange rate constants of PCr and PArg with ATP were calculated based on the equation:
where k is a rate constant describing the loss of magnetization because of exchange of saturated spins between PCr or PArg and ATP, T 1 0 is the apparent longitudinal relaxation time of PCr or PArg, M s is the steady-state phosphate signal under g-ATP saturation, and M o is the phosphate signal at its equilibrium value. M s was determined by fitting the decay of phosphate signal with saturation time using a monoexponential model, with M s expressed relative to M o measured with the mirror frequency saturation. Also, the exchange rate constant of P i with ATP was calculated based on the equation:
Estimation of T 1 0 of PCr, PArg and P i was accomplished by varying TR (0.8, 1.3, 1.8, 2.3, 3.3, 5.3, 7.3 and 10.3 s) and fitting with a monoexponential model. Following the calculation of k for PCr, PArg and P i , the unidirectional flux of ATP synthesis was calculated as the product of k and corresponding metabolite concentration using the following equations:
Flux PArg ! ATP ¼ k PArg ½ ð6Þ
Immunoblotting. Gastrocnemius muscles of the injected and contralateral limbs were performed by dissecting, freezing in liquid nitrogen and storing in À 80 1C. Upon removal from storage, the muscles were crushed on dry ice, tendons removed and homogenized in a radioimmune precipitation assay buffer (10 ml mg À 1 of dry muscle weight). Tissue homogenates were centrifuged to pellet debris and the total protein was measured in the supernatant using a Bradford procedure (Bio-Rad protein assay; BioRad Laboratories, Hercules, CA, USA). Protein from each muscle were separated by gel electrophoresis (SDS-polyacrylamide gel electrophoresis) and transferred to polyvinylidene fluoride membranes (Immobilon-P; Millipore, Bedford, MA, USA). Membranes were incubated in a blocking buffer and stirred for 90 min, and then incubated overnight at 4 1C with primary antibody diluted in 5% dried milk with tween/tris-buffered solution (TTBS). Primary antibodies included those for AK (1:10 000) and tubulin (1:3000). After washes and exposure to secondary antibodies recognizing rabbit (LI-COR Biosciences, Lincoln, NE, USA), specific bands were visualized by film using Image Quant LAS 4000 (GE Healthcare Biosciences, Pittsburgh, PA, USA).
Statistics
Longitudinal changes were compared using a one-way repeated measures analysis of variance (Prism Software, GraphPad, v6.0b, La Jolla, CA, USA). Comparisons between AK and CK fluxes, hindlimb regions and hindlimb with AK gene delivered vs contralateral hindlimbs and controls were evaluated using paired T-tests (Prism Software, GraphPad, v6.0b). Statistical significance was defined as a P-value less than or equal to 0.05. Data are reported as mean (s.d.) in the text and tables and mean (s.e.m.) in the figures.
